A coagulation Factor V inhibitor developed in a man 75 yr of age in association with an anaplastic malignancy and drug treatment (including the aminoglycoside antibiotic, gentamicin). The patient did not bleed abnormally, despite both surgical challenge and plasma Factor V activity of <1%. The inhibited plasma had grossly prolonged prothrombin and activated partial thromboplastin times, but a normal thrombin time. Mixing studies indicated progressive coagulation inhibition with normal plasma, but not with Factor V-deficient plasma, and reversal of coagulation inhibition by the addition of bovine Factor V to the patient's plasma. 1 ml of patient plasma inhibited the Factor V activity of 90 ml of normal human plasma. The inhibitor was isolated by sequential affinity chromatography on protein A-Sepharose and Factor V-Sepharose. The IgG isolate markedly inhibits the activity of prothrombinase assembled from purified Factors Xa and Va, calcium ion, and phospholipid vesicles, and partially inhibits prothrombinase assembled from purified Factor Xa, calcium ion, and normal platelets. The Factor V of platelets, however, appears relatively inaccessible to the antibody, inasmuch as platelets isolated from whole blood supplemented for 8 h with the antibody functioned normally with respect to platelet Factor V-mediated prothrombinase function. The absence of obvious hemorrhagic difficulties in the patient, the total inhibition of plasma Factor V by the inhibitor, and the apparent inaccessibility of platelet Factor V to the inhibitor specifically implicate platelet Factor V in the maintenance of hemostasis.
Introduction
Coagulation Factor V is a high molecular weight (330,000) singlechain glycoprotein that circulates in human plasma at a level of -7 7sg/ml (I1-3). It is the precursor of Factor Va, a two-subunit protein that is produced by limited proteolysis ofFactor V. Factor Va functions as an essential cofactor in the Factor Xa-catalyzed activation of the vitamin K-dependent zymogen, prothrombin, to the blood-clotting enzyme, thrombin. The reaction is catalyzed by the prothrombinase complex, which is composed of a molecule each of Factor Xa and Factor Va, a cellular (platelet) or phospholipid surface, and calcium ion (4) (5) (6) (7) (8) (9) (10) . Factor Va functions in the complex both by providing the equivalent of a receptor for Factor Xa and by enhancing, by an approximate factor of 3,000, the turnover number characterizing prothrombin activation (8, 9, 11, 12) . Although Factor Va has no known enzymatic properties of its own, its participation in prothrombin activation increases the rate of the process by four to five orders of magnitude under conditions that might typify those in vivo (7, 9) . Thus, studies of the reaction in vitro suggest that Factor Va is essential for normal hemostasis.
Approximately 80% of the Factor V of human whole blood is plasmatic, whereas -20% is associated with platelets (3). Thus, in blood two distinct pools of the cofactor exist. The relative contributions, however, of plasmatic and platelet Factor V to the hemostatic process are not clearly defined.
Both congenital deficiencies and spontaneously occurring inhibitors of human Factor V have been reported, although their recognized occurrence is rare . Spontaneously occurring inhibitors have proven to be antibodies that, in most instances, have occurred acutely in individuals who had been otherwise apparently normal with respect to hemostasis. The existence of Factor V inhibitors has typically been of short duration. No obvious common etiology for the occurrence of these inhibitors can be found among the cases reported to date, although in many instances (including the present one) they have been associated with the administration of aminoglycoside antibiotics (e.g., streptomycin, gentamicin, or kanamycin).
Although most individuals with severe congenital Factor V deficiency have had abnormal bleeding, bleeding tendencies in individuals with spontaneously occurring inhibitors of Factor V have been very variable. In some instances, bleeding has been severe, even fatal. In others, bleeding symptoms have ranged from mild to absent, even though inhibitors were present at sufficiently high titers to produce clotting abnormalities in vitro that would suggest life-threatening defects. Taken together, these observations have not provided an unequivocal assessment of whether Factor V is essential for normal hemostasis in vivo. Previously reported studies of patients with acquired Factor V inhibitors, however, have not differentiated the extent of functional deficiencies in both the plasma and the platelet Factor V pools.
Recently, Tracy et al. (44) reported studies ofa family, several members of which exhibited near-normal levels of Factor V antigen in both plasma and platelets, and had functionally normal plasma Factor V, but grossly abnormal platelet Factor V function. Associated with these characteristics was a profound bleeding tendency. These studies suggest an essential role for platelet Factor V in normal hemostasis. The hemostatic importance of platelet Factor V is also suggested by the experience of Chediak et al. (30) , who were able to manage successfully a bleeding diathesis associated with a Factor V inhibitor by transfusion of platelets, whereas transfusion of fresh-frozen plasma was inef-fective. Miletich et al. (42) , in studies of Factor Xa binding and prothrombinase activity expressed by platelets isolated from patients with Factor V deficiencies, found that the severity of clinical bleeding correlated better with decreased Factor Xa-platelet binding (presumably to Factor Va) and decreased platelet prothrombinase activity than with plasma Factor V levels. Studies reported in 1961 by Borchgrevink and Owren (45) suggest that, in congenital Factor V deficiency, transfusion of normal platelets might achieve hemostatic improvement for several days (as assessed by rebleeding from skin wounds) as contrasted with the more transient improvement of plasma Factor V activity. These several studies thus suggest that the Factor V of human platelets may be essential to hemostasis.
The present studies were undertaken to characterize a spontaneously occurring inhibitor of Factor V (2) . Vesicles ofphospholipid (phosphatidylserine-phosphatidylcholine, 1:3 wt/wt) were prepared as described by Barenholz et al. (47) . The fluorescent, reversible thrombin inhibitor, dansylarginine-N(3-ethyl-1,5-pentanediyl)amide (DAPA),' was prepared as described by Nesheim et al. (48) . Rabbit brain thromboplastin used in coagulation assays was prepared as described (2, 49) . All other reagents were of analytical quality.
Methods
Clotting assays. Detection and assay of the inhibitor were based on the ability ofthe inhibitor to prolong the prothrombin time ofnormal human plasma. Prothrombin time measurements typically were performed by adding in succession to a 13 X 85 mm glass tube fresh normal citrated human plasma (50 Ml), and the sample (50 Ml) containing the inhibitor. These were incubated 2 min at 370C. Thromboplastin was then added (50 Ml), and clotting was initiated at 370C with the addition ofan aliquot (50 Ml) of0.025 M CaCl2. The tube was rocked back and forth in a 370C
water bath and the time to clot formation, detected visually, was measured. Standard clotting assays for Factors II, V, VII, VIII, and X were performed as described previously (49) using the appropriate factor-deficient plasmas. Human Factor V-Sepharose was prepared by stirring human Factor V (3.5 mg in 35 ml of 0.1 M NaHCO3, 0.2 M NaCl, pH 8.5) with 4.0 ml of CH-Sepharose (activated with N-hydroxysuccinimide) at 22°C.
After I h, 1 M Tris HCl, pH 8.0 (10 ml) was added, and stirring was continued at 4°C overnight. The slurry was poured into a plastic column (12-cm3 disposable syringe with porous polyethylene frit) and washed with 0.02 M Tris -HCI, 0. 15 M NaCl, pH 7.4. The coupling efficiency, determined by intrinsic fluorescence (Aex = 280, Xem = 340), was -90%.
Isolation ofthe Factor Vinhibitor. Plasma (2.0 ml, 28 March sample) containing the inhibitor was applied at 22°C to a 3.5-ml column of protein A-Sepharose equilibrated in 0.1 M sodium phosphate (0.05% NaN3), pH 8.0. Flow was interrupted for 0.5 h and then recommenced with the same buffer. Washing was continued with 0.1 M sodium citrate (0.05% NaN3), pH 6.0. The inhibitor was then eluted in the antibody fraction using 0.1 M sodium citrate (0.05% NaN3), pH 3.0. The flow rate was -0.5 ml/min, and fractions of 2.0 ml were collected into 0.6 ml of I M Tris-HC1, pH 8.0. The inhibitory activity was monitored by clotting assays, performed by incubating an appropriately diluted sample (50 Ml) plus an aliquot (50 ul) of a mixture of human Factor V-deficient plasma and normal human plasma (9:1) for 2 min at 220C. An aliquot of thromboplastin (50 Ml) was added, and after a brief incubation at 370C, the prothrombin time ofthe sample was measured after initiation of clotting with an aliquot (50 Ml) of 0.025 M CaCl2. The relationship between inhibitor concentration and clotting time was established with serial dilutions ofthe starting plasma, the inhibitor content ofwhich was defined as 100 U/ml (this value was chosen because neutralization studies had indicated that the inhibitor present in I ml of patient plasma would neutralize the Factor V of -100 ml of normal human plasma, which by conventional definition has a Factor V content of I U/ml). Factor V antigen levels in the starting plasma and in the fractions obtained upon chromatography with protein A-Sepharose were determined by radioimmunoassay as described previously (3) . The fractions with inhibitor activity were pooled, dialyzed against 0.02 M TriseHCI, 0.15 M NaCI, pH 7.4 , and applied to a column of human Factor V-Sepharose equilibrated at 220C in the same buffer. The flow rate was -0.5 ml/min, and fractions of 4.0 ml were collected. The column was washed with the same buffer, and the inhibitor was eluted with 0.1 M glycine, 0.5 M NaCI, pH 2.8. The eluate of low pH (-2.0 ml/fraction) was collected into tubes containing 0.3 ml 1 M TristHCI, pH 8.0, in order to avoid prolonged exposure to low pH conditions. The absorbance (A, 280 nm) and inhibitor activity of the fractions were then determined.
Electrophoretic analysis. The material of the fractions obtained at pH 3.0 from protein A-Sepharose and pH 2.8 from human Factor VSepharose was analyzed by polyacrylamide slab gel electrophoresis (5-15% acrylamide gradient) in the presence of sodium dodecyl sulfate, using the alkaline discontinuous buffer system as described by Neville (50) (44) . The platelets were suspended at 1.2 X 1.09/ml. Aliquots (0.3 ml) were either activated with thrombin (1.0 U/ml, 2 min, 22QC) or were not stimulated, and the activity ofthe platelets to provide Factor Va and the catalytic surface of prothrombinase was determined fluorometrically by measurements ofthe rate ofprothrombin activation and thrombin generation. These measurements were performed as described above.
Results
Properties ofthe inhibitor as determined by clotting assays. The inhibitor was initially detected by virtue of its ability to prolong the clotting times of standard clotting assays. The coagulation test profile is listed in Table I . These data indicated a markedly prolonged prothrombin time and activated partial thromboplastin time, and a nearly normal thrombin time. The results obtained from the platelet neutralization procedure (52) suggested that the patient's inhibitor was not a "lupus anticoagulant." Assays for coagulation Factors 1I, VII, Vill, and X were inhibited as evidenced by higher apparent values upon dilution of the samples. Of those factors assayed, Factor V levels were the lowest, suggesting the possibility of a Factor V inhibitor. After passage ofthe plasma sample through protein A-Sepharose, assays for Factors II, VII, and X were not inhibited and yielded normal values. This procedure, however, did not restore Factor V activity.
As a test of the hypothesis that the inhibitor was directed against Factor V, its time course of inhibition was determined in normal or Factor V-deficient plasma. An aliquot (2.5 Ml) of The specificity of the inhibitor was investigated by supplementing the patient plasma with purified bovine Factor V to levels ranging from 0 to 100 Mg/ml. (The Factor V content of normal human plasma is typically -7 ug/ml, [3] .) For comparison, human Factor V-deficient plasma was similarly supplemented. After a period ofincubation (2 min), the prothrombin times of the supplemented samples were determined. In the absence of bovine Factor V, the prothrombin times of both the patient plasma and the Factor V-deficient plasma samples were grossly prolonged at .120 s. With increasing amounts ofbovine Factor V, however, the prothrombin times of both specimens shortened to values near that of normal plasma. These observations indicated that the patient's inhibitor was specific for human Factor V (relative to bovine Factor V). In addition, because the patient's plasma would clot normally if supplemented with a suitable source ofFactor V, the defect that yielded a prolonged prothrombin time in the absence of the supplement most likely was the inhibition of the endogenous Factor V of the sample.
An estimation of the quantity of the inhibitor present in the patient's plasma was determined by adding the patient's plasma in various volumes to a fixed volume of normal human plasma, and subsequently determining the prothrombin time of the mixture. The results of such an experiment are shown in Fig. 2 . Isolation of the inhibitor by affinity chromatography. The inhibitor was isolated by affinity chromatography ofthe patient's plasma on protein A-Sepharose followed by human Factor VSepharose. Total protein (A280 nm) and inhibitor activity (clotting assay) were measured. Chromatography on protein A-Sepharose (not shown) quantitatively removed the inhibitor from the plasma sample. In addition, the plasma recovered by flowthrough from the protein A-Sepharose chromatography could be assayed for coagulation Factors II, V, VII, and X without interference (Table I ). The clotting assays indicated that the plasma content ofFactors II, VII, and X was normal after passage through protein A-Sepharose, whereas Factor V levels were <1% of normal. In addition to clotting assays, radioimmunometric analysis was performed for Factor V (3). The starting plasma level of Factor V antigen was 10 lug/ml before chromatography, and was .1 sg/ml afterwards. The immunologically detectable Factor V was found in the low pH eluate ofthe chromatography, indicating that it co-chromatographed with the inhibitor on protein A-Sepharose. When normal plasma was chromatographed on protein A-Sepharose, the Factor V of the sample was not retained by the column. Thus, the retention of Factor V on the column after chromatography of the patient's plasma further suggests that the inhibitor is directed against Factor V. The yield of inhibitor upon chromatography on protein A-Sepharose was essentially quantitative (200 U applied, 190 U recovered at pH 3.0).
Subsequent chromatography of the inhibitor on Factor VSepharose is indicated in Fig. 3 . Upon application ofthe sample and continued washing at neutral pH, some inhibitor activity was retarded, but not retained by the column. This was presumed to reflect an overloading phenomenon, but no efforts were made to confirm this by rechromatography. The vast majority of the protein ofthe sample was recovered in the application and wash of neutral pH (.99%), whereas the remainder of the protein (-1%) and an appreciable quantity of inhibitory activity was recovered upon elution at pH 2.8. The two steps of chromatography provided a 13 1-fold purification ofthe inhibitor, and -130 1Ag protein from 2 ml of plasma. The overall yield was 17%. The relatively poor yield was due in part to the apparent limited capacity of the Factor V-Sepharose column.
Analysis ofthe inhibitor by gel electrophoresis. Samples obtained upon elution at low pH from protein A-Sepharose and human Factor V-Sepharose are shown in Fig. 4 . The sample obtained after protein A-Sepharose chromatography had electrophoretic mobility typical of plasma IgG, migrating with apparent molecular weight of 150,000 (nonreduced sample) and Studies ofthe accessibility ofplatelet Factor Vto the inhibitor. 5 The IgG fraction isolated from normal or patient plasma was * added to whole blood. After 1 or 8 h of incubation at 370C, nan Factor platelets were isolated from the blood and their capacity to sup-J (purified by port prothrombin activation in the presence of added Factor Xa 3 March plasma was studied. In both instances, prothrombinase activity was deis IgG greatly termined before and after stimulation of the platelets with 3epharose at thrombin. The time course of thrombin generation of platelets, recovered from blood incubated for 8 h with normal or patient IgG, is shown in Fig. 6 . The reaction profiles are essentially indistinguishable, indicating that the Factor V activity of the rent molecular two sets of platelets was essentially intact, which in turn suggests ,). The sample that the platelet Factor V was not accessible to the inhibitor ,or V-Sepharose during the course of incubation of the inhibitor and whole blood. Figure 6 . Influence of normal (A) or patient (B) IgG on the capability of normal platelets, isolated from whole blood supplemented with IgG for 8 h, to support prothrombinase activity in the absence of exogenous Factor V/Va. Equivalent amounts of normal IgG or patient IgG (from 18 April plasma specimen), isolated by affinity chromatography on protein A-Sepharose, were incubated with normal whole blood (37°C, 8 h) after which the platelets were isolated, washed, and thrombin-stimulated (1.0 U/ml, 2 min). Prothrombinase activity was quantitated by fluorometric determination of the rate of thrombin formation after initiation of the reaction with enzyme (Xa) added to a mixture containing platelets, prothrombin, DAPA, and Ca2". Although the Factor V activity of the plasma from blood supplemented with patient IgG (B) was markedly inhibited (plasma prothrombin time (PT) = 76.8 s; control plasma PT = 17.8 s), platelets isolated from inhibitor-supplemented blood (B) were indistinguishable from platelets isolated from the same blood supplemented with allogeneic IgG (A) with respect to their capability to support platelet Factor V/Va-dependent prothrombinase activity. groups ofplatelets were those obtained before stimulation ofthe platelets. Those platelets incubated with the patient's IgG were consistently less active before thrombin stimulation than those incubated with normal IgG. Both groups of platelets yielded similar activity after stimulation, however. These data imply that the inhibitor may have functioned to prevent partial, adventitious activation of the platelets during the prolonged incubation. The results of these studies are summarized in Table II .
Discussion
The results ofthe present study indicate that this patient'ssFactor V inhibitor is an IgG antibody. The antibody was acutely acquired in association with drug treatment (including the aminoglycoside antibiotic, gentamicin) of a patient who had disseminated malignancy. At the times of initial blood sampling, the titer of the antibody exceeded the Factor V level of normal plasma by a factor of 100. 3 wk after initial chemotherapy, the antibody titer exceeded plasma Factor V levels by 10-fold. In spite of the relatively high titer of inhibition and profound inhibition of plasma Factor V, the patient displayed no bleeding tendencies even upon surgical challenge. The antibody profoundly inhibited Factor V either in plasma or in a system of purified components (295% inhibition). In addition, the inhibitor appears specific for human Factor V. The antibody also (18) . Factor V inhibitors have arisen in association with recent surgical operations, blood transfusions, tuberculous infections, and/or administration of aminoglycoside antibiotics (e.g., streptomycin, gentamicin, or kanamycin). In all instances in which the inhibitors were characterized, they have been IgG antibodies. Further characterization in two instances has elucidated antibodies of IgG4 subclass, and in one case monoclonality was asserted (53) . It is of interest that acquired inhibitors ofFactor VIII, a coagulation protein structurally and functionally homologous with Factor V (54), have frequently been of IgG4 subclass (40, 55) . Characteristically, the existence of anti-Factor V antibodies has been transient. In some instances human Factor V inhibitors have been found to be inactive toward Factor V of other mammals. In the majority of the cases, some bleeding tendency has been observed, but only occasionally has the bleeding tendency proven fatal. In some cases, including the present one, no abnormal bleeding has been observed, despite surgical challenge in the presence of total or nearly total inhibition of plasma Factor V activity. Generally, the estimated antibody titer correlates with the occurrence of bleeding and its severity (Table IV) . Platelets contain -20% of the Factor V of human blood and comprise -0. 16% ofthe volume ofhuman blood. Therefore, the nominal Factor V concentration of platelets exceeds that of plasma by an approximate factor of 100 (Fig. 7) . Thus, in a situation involving a local accumulation of platelets with an appreciable exclusion of plasma, a "rapid" release or exposure of Factor V which, up to the point of exposure, had been protected from the antibody, might create sufficiently high local concentrations of Factor V to overwhelm an inhibitor, even though its titer was high relative to plasma levels of Factor V. The patient studied here had a Factor V inhibitor titer of approximately 100 and did not bleed; a patient with a titer of approximately 1,500, however, experienced hemorrhagic difficulties that proved fatal (27) .
The lack of tendencies to bleed in the presence of Factor V inhibitors with titers substantially exceeding plasma Factor V levels may be reconciled through considerations of the relative inaccessibility of platelet Factor V to the inhibitor, and the concentration of platelet Factor V relative to that of plasma Factor V. These concepts are suggested by Fig. 7 . Two pools of Factor V are depicted, one in platelets, the other in plasma. Although the platelets contain only 20% of the total Factor V of whole blood, they comprise such a relatively small volume that their formal concentration of Factor V exceeds that of plasma by >100-fold. The inhibitor level present in this patient's whole blood was sufficient to neutralize 90 times the Factor V content ofwhole blood (including platelets). Platelet Factor V, however, appeared relatively inaccessible to this inhibitor in whole blood. Thus, under conditions in which platelets might accumulate, as in hemostatic plug formation, plasma (and inhibitor) might be largely excluded. If the platelets then were to release or expose their Factor V, the "local" concentration (and therefore the amount) ofFactor V expressed might be sufficient to overwhelm the inhibitor locally. A phenomenon such as this would account for the lack ofbleeding under circumstances where plasma Factor V is completely neutralized by a relatively high-titer antibody whereas platelet Factor V remains intact.
